projects in our pipeline 21 new molecular entities in our late-stage pipeline 3 new molecular entities under review Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in ...
ASTRAZENECA WILL make out big with its acquisition of Gaithersburg,Md.-based MedImmune,one of the top 10 leading biotechnology companies in the world.Announced late last month and expected to close this June,the 15.6bn proposed acquisition will boost AstraZeneca's weak pipeline and gives the ...
Discover how we champion inclusion and diversity at AstraZeneca We have 199 projects in our pipeline View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres ...
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024 7 November 2024 AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA ...
AstraZeneca's drug pipeline has evolved significantly under CEO Pascal Soriot since he took over more than a decade ago, and new technologies such as antibody-drug conjugates are making up a rising proportion of its portfolio of future cancer therapies....
7 October 2024 AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy AstraZeneca has entered into an exclusive license agreement with CSPC PharmaceuticalGroupLtd(CSPC) to advance the development of an early stage, novel small molecule Lipoprotein...
The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A ...
More global research and innovation programs will be introduced into China on the basis that the company has around 150 pipeline projects in China, among which 90 percent are progressing neck to neck with relevant global prog...
AstraZeneca has announced plans to invest in strategic research and development centres in the UK, the US and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation. The proposals are designed to: ...
Our pipeline includes around 25 therapies and therapy combinations across CVRM diseases. We are exploring therapies to manage life-threatening complications of CKD, such as hyperkalaemia and anemia, and therapies to modify the progressive decline of the disease itself. We are, for instance, ...